A Validated Highly Sensitive Microsatellite Instability Assay Accurately Identifies Individuals Harboring Biallelic Germline PMS2 Pathogenic Variants in Constitutional Mismatch Repair Deficiency

Other authors

Institut Català de la Salut

[Marín F, Canet-Hermida J] Hereditary Cancer Group, Molecular Mechanisms and Experimental Therapy in Oncology Program, Institut d’Investigació Biomèdica de Bellvitge (IDIBELL), L’Hospitalet de Llobregat, Barcelona, Spain. CIBER Oncología (CIBERONC), Instituto Salud Carlos III, Madrid, Spain. [Bianchi V, Chung J] The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, ON, Canada. Program in Genetics and Genome Biology, The Hospital for Sick Children, Toronto, ON, Canada. [Wimmer K] Institute of Human Genetics, Medical University of Innsbruck, Innsbruck, Austria. [Foulkes W] Cancer Axis, Lady Davis Institute, Jewish General Hospital, Montreal, QC, Canada. Cancer Research Program, Research Institute of the McGill University Health Centre, Montreal, QC, Canada. [Sábado C] Servei d'Hematologia i Oncologia Pediàtriques, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Carrasco E] Hereditary Cancer Genetics Group, Medical Oncology Department, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain

Vall d'Hebron Barcelona Hospital Campus

Publication date

2024-05-21T09:23:43Z

2024-05-21T09:23:43Z

2024-05-02



Abstract

Inestabilitat de microsatèl·lits; Variants patògenes


Microsatellite Instability; Pathogenic variants


Inestabilidad de microsatélites; Variantes patógenas


Background Constitutional mismatch repair deficiency (CMMRD) is a rare and extraordinarily penetrant childhood-onset cancer predisposition syndrome. Genetic diagnosis is often hampered by the identification of mismatch repair (MMR) variants of unknown significance and difficulties in PMS2 analysis, the most frequently mutated gene in CMMRD. We present the validation of a robust functional tool for CMMRD diagnosis and the characterization of microsatellite instability (MSI) patterns in blood and tumors. Methods The highly sensitive assessment of MSI (hs-MSI) was tested on a blinded cohort of 66 blood samples and 24 CMMRD tumor samples. Hs-MSI scores were compared with low-pass genomic instability scores (LOGIC/MMRDness). The correlation of hs-MSI scores in blood with age of cancer onset and the distribution of insertion-deletion (indel) variants in microsatellites were analyzed in a series of 169 individuals (n = 68 CMMRD, n = 124 non-CMMRD). Results Hs-MSI achieved high accuracy in the identification of CMMRD in blood (sensitivity 98.5% and specificity 100%) and detected MSI in CMMRD-associated tumors. Hs-MSI had a strong positive correlation with whole low-pass genomic instability LOGIC scores (r = 0.89, P = 2.2e-15 in blood and r = 0.82, P = 7e-3 in tumors). Indel distribution identified PMS2 pathogenic variant (PV) carriers from other biallelic MMR gene PV carriers with an accuracy of 0.997. Higher hs-MSI scores correlated with younger age at diagnosis of the first tumor (r = −0.43, P = 0.011). Conclusions Our study confirms the accuracy of the hs-MSI assay as ancillary testing for CMMRD diagnosis, which can also characterize MSI patterns in CMMRD-associated cancers. Hs-MSI is a powerful tool to pinpoint PMS2 as the affected germline gene and thus potentially personalize cancer risk.


This work was conducted with the contribution of Fundación La Marató de TV3 (grant 202028–30), the Spanish Ministry of Science and Innovation, which is part of Agencia Estatal de Investigación (AEI), through the Retos Investigación grant (PID2019-111254RB-I00/DOI: 10.13039/501100011033). This study was also supported by CIBERONC (CB16/12/00234). Furthermore, this work counted on the support from the Secretariat for Universities and Research of the Department of Business and Knowledge of the Generalitat de Catalunya grant to support the activities of research groups 2021_01112.

Document Type

Article


Published version

Language

English

Publisher

Oxford University Press

Related items

Clinical Chemistry;70(5)

https://doi.org/10.1093/clinchem/hvae027

Recommended citation

This citation was generated automatically.

Rights

Attribution 4.0 International

http://creativecommons.org/licenses/by/4.0/

This item appears in the following Collection(s)